10582385 - GAU: 1615

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

s	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/582,385-Conf. #2824	
	NFORMATION	N DI	SCLOSURE	Filing Date	August 15, 2007	
(STATEMENT I	3Y /	APPLICANT	First Named Inventor	Marco Antonio SANTINI	
				Art Unit	1615	
	(Use as many sheets as necessary)			Examiner Name	M. S. Mercier	
Shee	t 1	of	2	Attorney Docket Number	4705-0121PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA*	US-5,504,102-A	04-02-1996	Agharkar et al.		
	AB*	US-5,733,888	03-31-1998	Carver et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Ringel, I., et al., "Taxol is Converted to 7-Epitaxol, a Biologically Active Isomer, in Cell Culture Medium," J. Pharma. and Experimental Therapeutics, Vol 242, No 2, pp 692-698 (1987)	
	СВ	Szebeni, J., et al., "Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an <i>In Vitro</i> Study," J. Natl. Cancer Institute, Vol 90, No 4, pp 300-306 (1998)	
	СС	Kraemer, I., "Stabiilty of new and old docetaxel formulation," Johannes Gutenerg Univ., Mainz, Germany, Pharm Ztg, Vol 145, pp 32-34 (2000)	√
	CD	Cresteil, T., et al., "Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity Relationship," Drug Metab. and Disposition, Vol 30, No 4, pp 438-445 (2002)	
	CE	Wahl, A., et al., "Rearrangement Reactions of Taxanes: Structural Modifications of 10- Deacetylbaccatine III.," Tetrahedron, Vol 48, No 34, pp 6965-6974 (1992)	
	CF	van Zuylen, L., et al., "Role of formulation vehicles in taxane pharmacology," Investigational New Drugs, Vol 19, pp 125-141 (2001)	
	CG	Samaranayake, G., et al., "Modified Taxols. 5.1 Reaction of Taxol with Electrophilic Reagents and Preparation of a Rearranged Taxol Derivative with Tubulin Assembly Activity," J. Org. Chem., Vol 56, No 17, pp 5114-5119 (1991)	

-			
Examiner		Date	
0:	/Maliaga Margiar/ (02/05/2010)	12410	
Signature	/ivielissa iviercier/ (02/05/2010)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.